Yahoo Web Search

  1. Ad
    related to Richard A. Gonzalez
  1. Is Allergan a Good Deal for AbbVie?

    Zacks via Yahoo FinanceJun 26 21:51 PM

    The purchase consideration of $188.24 per share therefore works out to a 45% premium to its last trading price on Monday. Allergan’s CEO, Brent Saunders, will join AbbVie’s board while ...

  2. Let’s parse the big news out of the health care acquisitions world—AbbVie announced on Tuesday that it will buy Allergan in a deal valued at about $63 billion, a 45% premium on ...

  3. AbbVie announced on Tuesday that it will buy Allergan in a deal valued at about $63 billion, a 45% premium on Allergan’s most recent closing stock price. The proposed M&A will ...

  4. AbbVie has long been under pressure to diversify its portfolio and its shares have lost more than a third of their value since January 2018 over concerns about Humira. AbbVie Chief Executive ...

  5. “This is a transformational transaction for both companies and achieves unique and complementary strategic objectives,” said AbbVie CEO and Chairman Richard Gonzalez in ...

  6. Edited Transcript of AMBA earnings conference call or presentation 4-Jun-19 8:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceJun 06 21:07 PM

    Needham & Company, LLC, Research Division - Senior Analyst * Richard Cutts Shannon Craig-Hallum Capital Group LLC, Research... Fiscal 2020 Earnings Call. (Operator Instructions) As a ...

  7. AbbVie to buy Allergan for $63B

    Fox Business via Yahoo FinanceJun 25 10:57 AM

    a cash and stock deal, with the transaction equity value based on AbbVie’s closing stock price of $78.45 on Monday. "This is a transformational transaction for both companies and ...

  8. Big drug hating politicians may want to think twice before hopping on the boob tube or working behind the scenes to attack and prevent a fresh wave of pharma industry consolidation. In ...

  9. AbbVie makes $63B bid for Botox maker Allergan

    Associated Press via Yahoo FinanceJun 25 18:38 PM

    Facing competition for the world's top-selling drug, AbbVie is jumping on this year's pharmaceutical merger bandwagon with a $63 billion bid for Botox maker Allergan that's meant to spur ...

  10. Abbvie Drops by a Record as Allergan Deal Fails to End Doubts

    Bloomberg via Yahoo FinanceJun 25 20:05 PM

    AbbVie will pay $188.24 a share in cash and stock, according to a statement, a 45% premium to Allergan’s closing price on Monday. “Allergan, with its well-known Botox, is ...

  1. Ads
    related to Richard A. Gonzalez